Clinical trials: Schizophrenia Disorders
Suicidal Ideation, Major Depressive Disorder
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse …
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- LAP-ST vs ECT (NCT06529029)
- Testing
- Sigma-Stim, RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michigan State University
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Psychotic Disorder, Obesity
Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study
This study is a feasibility study of a multi-component intervention to enhance healthy living among young people with psychotic disorders, specifically targeting smoking and weight.
- Conditions
- Psychotic Disorder, Obesity, Behavior, Addictive
- Trial name
- NCT00350311
- Testing
- nicotine transdermal patch/lozenge
- Where
- 4 sites in Australia
- Volunteers
- 43 people
- Sponsor
- The University of New South Wales
Schizophrenia
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
This is a prospective, 8-day, randomized, double-blind, placebo-controlled, sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single escalating oral doses of NW-3509A in healthy male volunteers.
- Trial name
- NCT01955564
- Testing
- NW-3509a
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
Modafinil Effects on Cognition in Schizophrenia Patients
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language.
- Trial name
- InO (NCT00711464)
- Testing
- modafinil (M1, M2, M4)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia
Treating Thought Problems in Patients With Schizophrenia
This study will compare Cognitive Adaptation Training (CAT) to minimal schizophrenia treatment. This study will also determine whether the intensity of CAT can be reduced and still provide benefits to patients with schizophrenia.
- Trial name
- NCT00051740
- Testing
- Cognitive Adaptation Therapy (CAT), Minimal Environmental Supports (MES)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Normal and Abnormal ERP During ToM and Emotional Conflicts in Schizophrenia
Case-control comparison of clinical population, interventional and single-center research.
- Trial name
- SERC (NCT02896374)
- Testing
- Theory of mind without visual cues
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Versailles Hospital
Schizophrenia
Treatment for First-Episode Schizophrenia
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
- Trial name
- NCT00000374
- Testing
- Olanzapine, Risperidone
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Northwell Health
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Background: Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of patients suffer from oncological or dermatological diseases.
- Trial name
- NCT00535574
- Testing
- Bexarotene (Targretin LGD1069), bexarotene
- Where
- 3 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Beersheva Mental Health Center
Hallucinations, Auditory, Psychosis
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications.
- Trial name
- NCT04366518
- Testing
- Rivastigmine Transdermal System, Scopolamine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Schizophrenia
Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
Schizophrenia is a serious mental disorder with a global prevalence of 1%. The main cause of this condition is dysfunction in the signaling of neurotransmitters dopamine, serotonin, glutamate and Gamma-aminobutyric acid…
- Trial name
- NCT06236451
- Testing
- Aripiprazole, Risperidone
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Psychosis
Belief-updating, Speech and Psychosis
Psychotic illnesses are characterised by hallucinations, delusions, and disturbed thoughts; symptoms associated with high personal and societal costs.
- Trial name
- BASIS (NCT06042712)
- Volunteers
- 240 people
- Sponsor
- King's College London
Schizophrenia
Linagliptin in Schizophrenia Patients
Approximately one third of patients with schizophrenia show a poor response to standard treatment with antipsychotic medications.
- Trial name
- NCT01943019
- Testing
- Linagliptin
- Where
- Malaysia
- Volunteers
- 1 people
- Sponsor
- Monash University
Schizophrenia, Myelin Degeneration
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
The general objective of this interventional study is to explore the impact of long-acting arpiprazole on brain structure, in particular potential neurotrophic effects, neurogenetic and neuroprotective that could counteract the…
- Conditions
- Schizophrenia, Myelin Degeneration, Cognition Disorder
- Trial name
- NCT05322031
- Testing
- Aripiprazole
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846881
- Testing
- Iclepertin
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 611 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Epilepsy
A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
The purpose of this study is to evaluate the effect of valproic acid (VPA) on the pharmacokinetics (blood levels) of a single oral dose of an extended-release formulation of paliperidone in healthy male volunteers.
- Trial name
- NCT01060228
- Testing
- paliperidone ER, divalproex sodium ER
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia
This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.
- Trial name
- NCT01903837
- Testing
- Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose)
- Where
- 61 sites in United States, Bulgaria and 1 more
- Volunteers
- 347 people
- Sponsor
- Alkermes, Inc.
Psychosis
Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda
Background: Mental health services are most effective and equitable when designed, delivered, and evaluated in collaboration with people with lived experience of mental health conditions.
- Trial name
- SCAPE-U (NCT05863572)
- Testing
- Primary care health worker training, Community Health Workers Training, Home visits
- Where
- Uganda
- Volunteers
- 179 people
- Sponsor
- George Washington University
Insulin Resistance, Metabolic Syndrome X
Side Effects of Antipsychotic Medications
Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to…
- Conditions
- Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders
- Trial name
- NCT00363181
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Stanford University